Search results
Results from the WOW.Com Content Network
Monoamine oxidase A, also known as MAO-A, is an enzyme (E.C. 1.4.3.4) that in humans is encoded by the MAOA gene. [ 5 ] [ 6 ] This gene is one of two neighboring gene family members that encode mitochondrial enzymes which catalyze the oxidative deamination of amines , such as norepinephrine , serotonin and tyramine .
Monoamine oxidase A and B share roughly 70% of their structure and both have substrate binding sites that are predominantly hydrophobic. Two tyrosine residues (398, 435 within MAO-B , 407 and 444 within MAO-A ) in the binding pocket that are commonly involved in inhibitor activity have been hypothesized to be relevant to orienting substrates ...
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as effective antidepressants , especially for treatment-resistant depression and atypical depression . [ 1 ]
Brunner syndrome is caused by a monoamine oxidase A (MAOA) deficiency, which leads to an excess of monoamines in the brain, such as serotonin, dopamine, and norepinephrine (noradrenaline). In both mice and humans, a mutation was located on the eighth exon of the MAO-A gene, which created a dysfunctional MAO-A gene.
Flavin-containing amine oxidoreductases are a family of various amine oxidases, including maize polyamine oxidase (PAO), [2] L-amino acid oxidases (LAO) and various flavin containing monoamine oxidases (MAO). The aligned region includes the flavin binding site of these enzymes.
11 Monoamine oxidase inhibitors (MAOIs) Toggle Monoamine oxidase inhibitors (MAOIs) subsection. 11.1 Irreversible. 11.1.1 Non-selective. 11.1.2 Selective for MAO-B ...
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. [1] The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.
Isocarboxazid, as well as other MAOIs, increase the levels of the monoamine neurotransmitters serotonin, dopamine, norepinephrine, epinephrine, melatonin, and phenethylamine in the brain. [ 11 ] Classical MAOIs, including isocarboxazid, are used only rarely due to prominent food and drug interactions and have been largely superseded by newer ...